Objective
The objective of the overall innovation project is to develop a novel instrument to measure and control pharmaceutical drug potency during manufacture at sub-second analysis speeds. This will significantly reduce the cost of quality testing, reduce the dosage variability that a patient receives, reduce production waste and solvent disposal and address challenging new regulatory testing guidelines.
Pharmaceutical companies, in response to regulators (such as the US FDA) setting direction and guidance, need to better understand and control their processes. Real-time release testing (RTRT) and Quality by Design (QbD) are promoted by regulators as their vision of where quality must go; pharmacopeia guidance supports that vision.
Cobalt has developed a successful, patented, high speed quantitative analysis technology called transmission Raman spectroscopy (TRS), which measures drug potency of intact tablets and capsules. When used during production (“on-line”) in combination with an automated physical tablet testing system, TRS will enable immediate release of drug product without “off-line” analysis in a quality control (QC) laboratory.
Field of science
- /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug
- /natural sciences/chemical sciences/analytical chemistry/spectroscopy
- /natural sciences/chemical sciences/inorganic chemistry/inorganic compounds
- /natural sciences/chemical sciences/analytical chemistry/quantitative analysis
Programme(s)
Call for proposal
H2020-SMEINST-1-2014
See other projects for this call
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
OX14 4SD Abingdon Oxfordshire
United Kingdom
